Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02907281 · ClinicalTrials.gov registry record
Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis
A clinical trial of Multiple Sclerosis and RRMS, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 414
- Enrollment target
- 20
- Study locations
NCT02907281: Completed study of Multiple Sclerosis and RRMS, sponsored by Novartis Pharmaceuticals.
NCT02907281 is a study of Multiple Sclerosis and RRMS that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 414 participants, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (29% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02907281, a study of Multiple Sclerosis and RRMS, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 414 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a 3-year, pharmacologically non-interventional study to evaluate OCT as an outcome measure in patients with relapsing remitting multiple sclerosis (RRMS). Approximately 350 RRMS patients, either untreated or treated with an approved MS disease-modifying therapy and approximately 70 reference subjects without ophthalmologic or neurologic disease are enrolled. No study medications are provided. Patients on disease-modifying therapy are treated according to the local prescribing information. For each MS patient and each reference subject, the study consists of Screening (up to 1 month), Baseline, and a 36-month longitudinal data collection phase. Eligibility will be confirmed during Screening.
Primary Outcome
evaluate change in RNFL thickness in relapsing remitting multiple sclerosis (RRMS) patients followed for up to 36 months compared to a group of reference subjects (without neurologic or ophthalmic disease) to determine whether the technology is sufficiently sensitive to disease and to change over time.
Conditions Studied
Interventions
- OTHER Observational
Study Locations (20)
Other
- Novartis Investigative Site - Prague
- Novartis Investigative Site - Copenhagen
- Novartis Investigative Site - Berlin
- Novartis Investigative Site - Magdeburg
- Novartis Investigative Site - Bari
- Novartis Investigative Site - Genova
- Novartis Investigative Site - Montichiari
- Novartis Investigative Site - Padua
- Novartis Investigative Site - Roma
California
- Novartis Investigative Site - San Francisco
- Novartis Investigative Site - Torrance
Iowa
- Novartis Investigative Site - Iowa City
Maryland
- Novartis Investigative Site - Baltimore
Pennsylvania
- Novartis Investigative Site - Philadelphia
New South Wales
- Novartis Investigative Site - Camperdown
Victoria
- Novartis Investigative Site - Parkville
Alberta
- Novartis Investigative Site - Calgary
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 414 participants |
| Start Date | 2012-05-29 |
| Est. Completion | 2017-07-24 |
What the finished NCT02907281 record still lists
NCT02907281 is an observational study that tracks outcomes without assigning an intervention. The registered 414 participants enrollment target is mid-sized for trials with a published cap, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (29% lower).
The record links to 2 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Observational is the first listed.
NCT02907281 names 20 study sites across 11 states, led by Other, California, Iowa.
Frequently Asked Questions
What is clinical trial NCT02907281 about?
NCT02907281 is a clinical study titled "Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis". This is a 3-year, pharmacologically non-interventional study to evaluate OCT as an outcome measure in patients with relapsing remitting multiple sclerosis (RRMS). Approximately 350 RRMS patients, either untreated or treated with an approved MS disease-modifying therapy and approximately 70 referenc...
What is the current status of trial NCT02907281?
This trial is currently completed. The enrollment target is 414 participants. The study started on 2012-05-29. Estimated completion is 2017-07-24.
What conditions does trial NCT02907281 study?
This clinical trial studies the following conditions: Multiple Sclerosis, RRMS.
What interventions are being tested in trial NCT02907281?
The interventions under investigation include: Observational (OTHER).
Who is sponsoring clinical trial NCT02907281?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02907281 being conducted?
This trial has 20 study locations across California, Iowa, Maryland, Pennsylvania, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02907281's enrollment target sits among peer trials
414 45th of 315 higher than 271 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04776941 · 414 participants · NA
Expressive Writing for the Management of Stress in Cancer Survivors
- NCT06792552 · 414 participants · Phase 1
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
- NCT05142605 · 415 participants · NA
Evaluation of Grief Therapy Approaches for Bereaved Parents
- NCT03592472 · 413 participants · Phase 3
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI